Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMTREA: CBD + CBG + THC as Adjunctive Therapy for Chronic Migraine
NCT04989413Phase 3Terminated
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Oct 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol, cannabigerol, dronabinol in chronic migraine, sponsored by Hospital Israelita Albert Einstein. Started Oct 2022; status: terminated.
02
Drugs
cannabidiolcannabigeroldronabinol
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT04989413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989413.